Haemonetics Reports Strong Fiscal Year 2026 Close with Revenue Growth

Medical technology firm Haemonetics Corporation has released its financial outcomes for the fourth quarter and full fiscal year ending March 28, 2026. The company reported a substantial 9% increase in its global revenue for the full fiscal year, reaching $1.25 billion on an organic basis. Contributing to this overall growth, the Plasma franchise experienced a 13% organic revenue boost during the same period. This was primarily driven by the success of its innovative Persona® technology, which saw increased adoption and utilization throughout the year. The Hemostasis Management segment also showed a healthy 7% organic revenue increase, largely due to strong demand for its TEG® 6s device and related consumables. According to Yahoo Finance, Haemonetics’ Hospital business, excluding Hemostasis Management, recorded a 6% organic revenue rise. This growth was particularly notable in its North American operations, benefiting from strong performance in vascular closure products. The company’s strategic focus on these high-growth areas appears to be yielding positive results. For the fourth quarter of fiscal year 2026, Haemonetics reported a 7% rise in total organic revenue. The Plasma franchise continued its momentum with a 10% organic revenue increase in the quarter, again fueled by the Persona system. The Hemostasis Management business observed a 6% organic revenue uplift, reflecting ongoing demand for its specialized diagnostic tools. Looking ahead to fiscal year 2027, the company projects its total revenue to grow between 5% and 7% organically. This forecast includes an expected 7% to 9% organic revenue increase for the Plasma business, indicating continued confidence in this segment’s trajectory. The Hemostasis Management franchise is anticipated to achieve 5% to 7% organic revenue growth, while the rest of the Hospital business is projected to grow organically by 3% to 5%. Haemonetics is also estimating an adjusted earnings per share in the range of $4.10 to $4.30 for the upcoming fiscal year. These projections suggest a positive outlook from the company's leadership regarding its operational performance and market position in the coming year. The company’s sustained investment in research and development, alongside strategic market penetration, appears to be foundational to its future growth strategy.